About 800,000 nurses planning to leave the profession by 2027, data show
Fierce Healthcare
APRIL 14, 2023
About 800,000 nurses planning to leave the profession by 2027, data show dmuoio Fri, 04/14/2023 - 14:25
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Fierce Healthcare
APRIL 14, 2023
About 800,000 nurses planning to leave the profession by 2027, data show dmuoio Fri, 04/14/2023 - 14:25
pharmaphorum
MAY 19, 2023
Teva is eyeing $2.5bn in Austedo sales in 2027 Phil.Taylor Fri, 05/19/2023 - 09:41 Bookmark this
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
MARCH 27, 2023
percent between 2022 and 2027. Microbiology article: Pharmaceutical microbiology: key developments 2022… The post Rapid microbiology testing market growth expected 2022 to 2027 appeared first on European Pharmaceutical Review. According to the data, the market is forecasted to increase by $2,487.91 Don Whitley Scientific Ltd.,
Fierce Healthcare
MAY 10, 2023
17 health systems commit to hiring, promoting more low-income workers by 2027 dmuoio Wed, 05/10/2023 - 13:06
European Pharmaceutical Review
DECEMBER 9, 2022
billion by 2027 during the forecast period, due to the rise in ongoing clinical trials for oligonucleotide-based therapies in key therapeutic sectors such as oncology. billion by 2027 appeared first on European Pharmaceutical Review. The research projected a compound annual growth rate (CAGR) of 16.8 percent from $7.7 billion in 2022.
Pharmaceutical Technology
AUGUST 31, 2023
Alkermes settled the lawsuit with Teva, allowing the latter to market the generic version of Vivitrol from January 2027.
European Pharmaceutical Review
FEBRUARY 1, 2023
billion in 2027 at a compound annual growth rate (CAGR) of 12.5 The post Pharmaceutical sterility testing market to grow from $2.07b in 2027 appeared first on European Pharmaceutical Review. A recent market report showed that the global pharmaceutical sterility testing market is expected to grow from $2.07 billion in 2022 to $1.29
Fierce Healthcare
MARCH 21, 2023
by 2027: report pminemyer Tue, 03/21/2023 - 16:11 The payer services market could be worth $118.2B
Pharmacy Times
JANUARY 10, 2023
The report highlights the growth of personalized medicines with improved efficacy for rare, previously untreatable diseases.
BioPharm
OCTOBER 26, 2023
As CMOs continue to invest in cell culture capacity, some are expected to surpass top in-house companies.
Drug Store News
JANUARY 30, 2023
The underlying growth rate will be driven by new drug launches and wider use of recently launched brands despite efforts by payers to constrain their budgets, and the impact of lower-cost options.
Fierce Pharma
MARCH 7, 2024
By Eisai’s 2026 fiscal year—which ends in March 2027—the company figures its Alzheimer's disease drug Leqembi can bring home 290 billion Japanese yen (nearly $2 billion) in global revenues. Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion).
Fierce Pharma
AUGUST 30, 2023
After settling a patent case with Vivitrol maker Alkermes, Teva has gained a license to launch its generic version of the opioid dependence and alcohol dependence med years ahead of the drug's pate | Under the patent settlement, Teva will be able to launch its generic two years ahead of the 2029 patent expiration for Vivitrol.
Outsourcing Pharma
OCTOBER 24, 2023
Traditionally, the pharmaceutical landscape has been dominated by small molecules.
Fierce Pharma
DECEMBER 20, 2023
The sale is expected to go into effect in January 2027. . | In a deal worth around $116 million, Novartis is handing over a portfolio of “select ophthalmology brands” to Mumbai’s J.B. Chemicals & Pharmaceuticals. Until then, J.B. plans to distribute and market the medicines in India.
Drug Store News
APRIL 12, 2023
17, 2027, or earlier based on certain circumstances. Under the agreement, Dr. Reddy’s has the right to market its product beginning Nov.
STAT
OCTOBER 26, 2023
About 800,000 nurses plan to leave the workforce by 2027, and more than half of newly graduated nurses are leaving the profession within two years. The Kaiser strike is over, for now, but there is no clear resolution in place, and other strikes are still under way or on the horizon.
PharmExec
FEBRUARY 9, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Pharmaceutical Commerce
APRIL 5, 2023
Rise in value attributed to the ongoing decentralization of pharmacies.
STAT
JULY 24, 2023
The House Ways & Means Committee package includes a new provision that would ensure that patients in the Medicare program pay for medicines they pick up at the pharmacy counter based on the discounted price that insurers negotiate with drugmakers, instead of higher sticker prices, starting in 2027.
Pharmaceutical Technology
OCTOBER 6, 2023
Biologics are poised to overtake innovative small molecules in terms of sales revenue by 2027, with forecast sales of $120bn.
STAT
DECEMBER 7, 2023
One expires next year and the other in 2027, well beyond the original patent expiration date. The move meant that the company, which is now part of Bristol Myers Squibb, won several more years of valuable patent protection than it would have received had it applied for the extra patents when submitting its data to the FDA.
The Guardian - Pharmaceutical Industry
SEPTEMBER 21, 2023
The commission’s investigation was made public last week by the health department and the Health Justice Initiative (HJI) legal organisation at a media briefing of Médecins Sans Frontières (MSF).
Drug Store News
SEPTEMBER 6, 2023
Alkermes has granted Teva a license to market generic Vivitrol beginning in January 2027.
STAT
JANUARY 17, 2023
The number of health care-related artificial intelligence models on the market has increased steadily over the past decade, with the health care AI market expected to grow from $7 billion today to $67 billion in 2027.
The FDA Law Blog
NOVEMBER 9, 2022
In addition to reauthorizing for an additional five fiscal years—Fiscal Years 2023-2027—several drug, biological product, and medical device user fee provisions that were scheduled to sunset on September 30, 2022, FUFRA reauthorizes—but only through December 16, 2022—several other statutory provisions that were scheduled to expire.
Pharmaceutical Commerce
JANUARY 25, 2023
Annual report finds continuing impact of COVID-19 on global markets
European Pharmaceutical Review
FEBRUARY 27, 2024
The facility has been designed to meet the highest environmental sustainability standards, to help Amgen’s reach its target of carbon neutrality in all operations by 2027, the company noted. .” Amgen Ohio is nearly 300,000 ft 2 in size and will employ 400 full-time staff.
Pharmaceutical Technology
MARCH 15, 2023
The committee has also launched new targets for December 2027. Additionally, 50 of the private companies in the UK need to have a minimum of one ethnic minority director on the main board by December 2027. Under these targets, each FTSE 350 company will be required to set a percentage target for senior management positions.
Pharmafile
JANUARY 25, 2023
The facility is expected to become operational in 2027 and will create over 100 new jobs for manufacturing personnel. Lilly’s expansion is set to include the addition of further parenteral filling, device assembly and packaging capacity in order to meet the growing demand for the company’s incretin-based diabetes treatments and medications.
European Pharmaceutical Review
MARCH 14, 2024
A global Phase III clinical trial is being planned, with an expected regulatory submission in 2027. The data from the studies suggested that the vaccine has “blockbuster potential”, according to SK bioscience.
STAT
NOVEMBER 20, 2023
Under the new agreement, the level of allowed growth in drug sales will increase from 2% in 2024 to 4% by 2027. The current plan, which has drawn the ire of pharma companies, requires drug companies to pay rebates back to the U.K. if spending on medicines increases by more than 2% a year. Continue to STAT+ to read the full story…
pharmaphorum
JANUARY 4, 2022
An appeals court ruling has upheld the validity of a key US patent covering Gilenya (fingolimod), and issued a permanent injunction against HEC Pharma until it expires in December 2027. Generics could still appear on the US market before the end of 2027 however.
Pharma Mirror
JANUARY 26, 2023
billion by 2027. At the same time, Asia-Pacific pharma players expect their businesses to grow rapidly in the upcoming year. With an estimated CAGR of 10.5%, the APAC market is expected to reach a booming $64.96 Simultaneously, China remains the world’s biggest pharma producer, with an estimated value of around $573.5 billion in 2022.
European Pharmaceutical Review
OCTOBER 16, 2023
The new filling line is projected to be operational in 2027. Approximately 115 new jobs are expected to be created. Enhancing manufacturing capabilities The bioconjugates market is currently valued at $33 billion according to research by Lonza.
Roots Analysis
OCTOBER 4, 2023
during the period 2023-2035. during the period 2023-2035. during the period 2023-2035.
European Pharmaceutical Review
NOVEMBER 20, 2023
While the new site is anticipated to be operational at the start of 2027, the investment in Alzey is contingent upon finalisation of government permitting and local approvals, Eli Lilly stated. To support reliable medicine supply, since 2020, Eli Lilly has announced investments of over $11 billion in its global manufacturing footprint.
The deprescribing.org Blog
JUNE 2, 2023
Leads: Dr. Lisa McCarthy, Dr. Wade Thompson, Dr. Iliana Lega Contact: deprescribing@deprescribing.org Funder (2023-2027): Canadian Institutes of Health Research (CIHR) The post Deintensifying Diabetes Management for Older Adults Living in Long-Term Care appeared first on Deprescribing.org.
Pharmaceutical Technology
MAY 19, 2023
AbbVie anticipates Rinvoq sales to exceed $7.5bn in 2025 and for the peak revenues from both drugs to exceed Humira’s peak sales by 2027.
Pharma Mirror
APRIL 16, 2021
With increasing proclivity towards these pharmacies, the compounding pharmacies market is estimated to witness commendable growth over the coming years by registering a significant valuation of USD 15 billion by 2027. Recently, worldwide outbreak of COVID-19 has disrupted the supply chains delaying the delivery of raw materials which.
PharmaShots
APRIL 6, 2023
Under the BsuFA III program, in 2022, the US FDA has granted $5M new research funding for 5 research proposals ($1M per award per year) under the regulatory science pilot program BsUFA III (FY 2023-2027) was implemented on Oct 1st, 2022, followed by BsUFA I (FY 2023-2027) and BsUFA II (FY 2018– 2022) with the aim (demonstration projects): 1) (..)
European Pharmaceutical Review
OCTOBER 18, 2022
Global pharma contract manufacturing market to value $120bn by 2027… The post HPAPI contract manufacturing to value $14.6 billion by 2030 appeared first on European Pharmaceutical Review.
European Pharmaceutical Review
SEPTEMBER 21, 2023
The Novo Nordisk Foundation Cellerator is expected to be in operation in 2027. “We believe the Novo Nordisk Foundation Cellerator can be a leading player in Europe and a model for similar facilities around the world,” Professor Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation commented.
European Pharmaceutical Review
DECEMBER 2, 2022
The facility is planned for completion in 2027. The investment will support the addition of new technologies to ensure Pfizer is ready to facilitate the next generation of medical innovations, and to help increase capacity for licensed and pipeline products in oncology, rare disease, inflammation & immunology and internal medicines.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content